Pradaxa 150mg BiD should be continued for 3 months

Antiphospholipid antibody syndrome is a risk factor for recurrent thrombosis in patients with unprovoked PE. Extended use of anticoagulation can be considered and the risk-benefit ratio needs to be regularly re-assessed (IC classification).

This is a wrong response that could lead to potentially harmful results to the health.